Andrea Brugnolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5128079/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. International Psychogeriatrics, 2010, 22, 984-994.	1.0	195
2	Consistency of Neuropsychiatric Syndromes across Dementias: Results from the European Alzheimer Disease Consortium. Dementia and Geriatric Cognitive Disorders, 2008, 25, 1-8.	1.5	167
3	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging, 2012, 33, 2533-2550.	3.1	108
4	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of Nuclear Medicine, 2013, 54, 894-902.	5.0	108
5	Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 36-45.	6.4	95
6	Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. NeuroImage: Clinical, 2015, 7, 34-42.	2.7	85
7	Cognitiveâ€nigrostriatal relationships in de novo, drugâ€naÃ⁻ve Parkinson's disease patients: A [lâ€123]FPâ€CIT SPECT study. Movement Disorders, 2010, 25, 35-43.	3.9	83
8	Early identification of MCI converting to AD: a FDG PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2042-2052.	6.4	83
9	Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2191-2202.	6.4	77
10	Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: Correlations between sympathovagal activity, clinical features, and leptin levels. Journal of Endocrinological Investigation, 2007, 30, 356-362.	3.3	69
11	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. Journal of Alzheimer's Disease, 2015, 44, 815-826.	2.6	67
12	Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study. Movement Disorders, 2009, 24, 414-421.	3.9	63
13	Unawareness of Memory Deficit in Amnestic MCI: FDG-PET Findings. Journal of Alzheimer's Disease, 2010, 22, 993-1003.	2.6	59
14	Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD. Parkinsonism and Related Disorders, 2016, 29, 47-53.	2.2	57
15	Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease. Clinical Neurophysiology, 2005, 116, 364-375.	1.5	51
16	An updated Italian normative dataset for the Stroop color word test (SCWT). Neurological Sciences, 2016, 37, 365-372.	1.9	49
17	Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers. Movement Disorders, 2017, 32, 1738-1747.	3.9	43
18	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease. 2009. 17. 761-772.	2.6	42

Andrea Brugnolo

#	Article	IF	CITATIONS
19	MCI Patients Declining and Not-Declining at Mid-Term Follow-Up: FDG-PET Findings. Current Alzheimer Research, 2010, 7, 287-294.	1.4	41
20	Metabolic Correlates of Rey Auditory Verbal Learning Test in Elderly Subjects with Memory Complaints. Journal of Alzheimer's Disease, 2014, 39, 103-113.	2.6	39
21	Predicting the transition from normal aging to Alzheimer's disease: A statistical mechanistic evaluation of FDG-PET data. NeuroImage, 2016, 141, 282-290.	4.2	36
22	The factorial structure of the mini mental state examination (MMSE) in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2009, 49, 180-185.	3.0	34
23	What predicts cognitive decline in de novo Parkinson's disease?. Neurobiology of Aging, 2012, 33, 1127.e11-1127.e20.	3.1	34
24	Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2209-2218.	6.4	32
25	Neuroprogression as an Illness Trajectory in Bipolar Disorder: A Selective Review of the Current Literature. Brain Sciences, 2021, 11, 276.	2.3	31
26	Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 764-775.	6.4	30
27	18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2073-2083.	6.4	29
28	Cortical sources of awake scalp EEG in eating disorders. Clinical Neurophysiology, 2007, 118, 1213-1222.	1.5	23
29	Brain 18F-DOPA PET and cognition in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1062-1070.	6.4	23
30	Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiology of Aging, 2019, 76, 9-17.	3.1	23
31	Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2834-2845.	6.4	22
32	A normative study of the Italian printed word version of the free and cued selective reminding test. Neurological Sciences, 2015, 36, 1127-1134.	1.9	21
33	Parkinson's Disease Sleep Scale 2: application in an Italian population. Neurological Sciences, 2016, 37, 283-288.	1.9	21
34	Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study. Journal of Alzheimer's Disease, 2020, 74, 865-874.	2.6	21
35	Stroop interference task and single-photon emission tomography in anorexia: A preliminary report. International Journal of Eating Disorders, 2005, 38, 323-329.	4.0	20
36	Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD). Journal of the Neurological Sciences, 2011, 310, 31-35.	0.6	19

Andrea Brugnolo

#	Article	IF	CITATIONS
37	Cognitive impairment in late life bipolar disorder: Risk factors and clinical outcomes. Journal of Affective Disorders, 2019, 257, 166-172.	4.1	19
38	The fate of patients with REM sleep behavior disorder and mild cognitive impairment. Sleep Medicine, 2021, 79, 205-210.	1.6	19
39	Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease. Cortex, 2020, 130, 401-412.	2.4	16
40	The Von Restorff effect in ageing and Alzheimer's disease. Neurological Sciences, 2006, 27, 166-172.	1.9	15
41	The need of appropriate brain SPECT templates for SPM comparisons. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2008, 52, 89-98.	0.7	15
42	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease1. Journal of Alzheimer's Disease, 2019, 68, 383-394.	2.6	14
43	Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1263-1274.	6.4	12
44	99mTc-HMPAO and 99mTc-ECD brain uptake correlates of verbal memory in Alzheimer's disease. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2007, 51, 357-63.	0.7	12
45	The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease. Neurobiology of Aging, 2020, 96, 117-127.	3.1	11
46	Global cognitive impairment should be taken into account in SPECT–neuropsychology correlations: the example of verbal memory in very mild Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1186-1192.	6.4	10
47	Rapid eye movement sleep behavior disorder: A proofâ€ofâ€concept neuroprotection study for prodromal synucleinopathies. European Journal of Neurology, 2021, 28, 1210-1217.	3.3	9
48	The Reversed Clock Drawing Test Phenomenon in Alzheimer's Disease: A Perfusion SPECT Study. Dementia and Geriatric Cognitive Disorders, 2010, 29, 1-10.	1.5	8
49	Frontal Variant Alzheimer Disease or Frontotemporal Lobe Degeneration With Incidental Amyloidosis?. Alzheimer Disease and Associated Disorders, 2016, 30, 183-185.	1.3	8
50	The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer's Disease and Frontotemporal Dementia. Biomedicines, 2022, 10, 544.	3.2	8
51	Dopaminergic and Serotonergic Degeneration and Cortical [18 F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. Movement Disorders, 2021, 36, 2293-2302.	3.9	7
52	Stratification Tools for Diseaseâ€Modifying Trials in Prodromal Synucleinopathy. Movement Disorders, 2022, 37, 52-61.	3.9	7
53	The Italian Version of the Test Your Memory (TYM-I): A Tool to Detect Mild Cognitive Impairment in the Clinical Setting. Frontiers in Psychology, 2020, 11, 614920.	2.1	4
54	The Short Cognitive Evaluation Battery in Cognitive Disorders of the Elderly – Italian Version. Dementia and Geriatric Cognitive Disorders, 2012, 33, 255-265.	1.5	3

ANDREA BRUGNOLO

#	Article	IF	CITATIONS
55	Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD). Diagnostics, 2021, 11, 108.	2.6	3
56	Impaired access to semantic memory for the cognition of geographic space in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2010, 50, 198-201.	3.0	2
57	Polysomnographic correlates of sleep disturbances in de novo, drug naÃ⁻ve Parkinson's Disease. Neurological Sciences, 2021, , 1.	1.9	2
58	The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort. Journal of Alzheimer's Disease, 2022, 87, 887-899.	2.6	1
59	The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1945-1955.	2.8	1
60	P4-190: 18FDG PET Predicts Time to Disease Milestones in a Naturalistic Population of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease. , 2016, 12, P1094-P1095.		0